Company: BIAF
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010787
Chunk: 41

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 41
---
 454  
     74,445  
     —  
     74,899 

    Sale of common stock 
     —  
     —  
     1,600,000  
     11,200  
     2,488,800  
     —  
     2,500,000 

    Offering costs 
     —  
     —  
     —  
     —  
     (495,000) 
     —  
     (495,000)

    Net loss 
     —  
     —  
     —  
     —  
     —  
     (1,961,815) 
     (1,961,815)

    Balance at March 31, 2024 (unaudited) 
     —  
    $—  
     11,220,551  
    $78,515  
    $51,744,830  
    $(46,566,294) 
    $5,257,051 
  
    Balance 
     —  
    $—  
     11,220,551  
    $78,515  
    $51,744,830  
    $(46,566,294) 
    $5,257,051 

The accompanying notes are an integral part of these
condensed consolidated financial statements.

7

bioAffinity Technologies, Inc.

Unaudited Consolidated Statements of Cash Flows

(unaudited)

    2025  
    2024 

    Three Months Ended March 31, 

    2025  
    2024 

    Cash flows from operating activities 

    Net loss 
    $(2,660,417) 
    $(1,961,815)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation and amortization 
     154,588  
     149,637 
  
    Stock-based compensation expense 
     326,616  
     283,712 
  
    Changes in operating assets and liabilities: 

    Accounts and other receivables 
     175,460  
     (311,935)
  
    Inventory 
     (11,174) 
     8,997 
  
    Prepaid